In 2001 funding for AOCS was obtained from the US Department of Defence (DOD) to create Epidemiology and Bio-specimen Core facilities and for ascertainment of cases and controls from the eastern states (VIC, QLD, NSW, SA). This funding allowed the collection of extensive epidemiological data and collection of blood for genetic analyses and frozen tumour specimens for molecular studies.
Since 2003 funding from Cancer Councils in each state has enabled the establishment of a national AOCS Clinical Follow Up Core for the collection of vital treatment and clinical outcome information, now a major strength of AOCS. Cancer Council funding also allowed expansion of collection to TAS and WA so that patient recruitment is truly national.
In 2005, AOCS was successful in the NHMRC Project grant round and secured funding through to 2011 for on-going collection of clinical follow-up data, allowing collection of a minimum 5-year clinical follow up on all cases. In addition, we were successful in our 2005 NHMRC Enabling Grant application in obtaining funding to manage and maintain the AOCS Core Facilities through to 2010.
From June 2014 to 2017, AOCS was jointly funded by Ovarian Cancer Australia (OCA) and the PeterMac Foundation. This funding allowed AOCS to continue recruiting women whose disease had returned after primary treatment and has enabled our research into mechanisms of treatment resistance.
From 2017 to 2020, we will be partly funded by AstraZeneca Pty Ltd, a commercial company with interests in the outcome of the research. A sponsorship agreement has been signed between AstraZeneca Pty Ltd and the University of Sydney (funding recipient), in which AOCS retains ownership of the study.
We also have a cost-recovery mechanism whereby researchers utilising the resource are asked to contribute some funds towards the cost of providing all materials used to support their research.
Social Media